Samsung Partners with Alcedis to Use Wearable Data in Clinical Trials
三星與 Alcedis 合作，將穿戴裝置數據應用於臨床試驗
更新於: 2026年6月24日 上午04:45
On June 24, 2026, Samsung Electronics announced a strategic partnership with Alcedis, a German clinical research organization, to transform how clinical trials are conducted.
2026年6月24日，三星電子宣布與德國臨床研究組織Alcedis建立戰略夥伴關係，旨在革新臨床試驗的執行方式。
The collaboration focuses on integrating biometric data from the Samsung Galaxy Watch into drug development processes.
此項合作重點在於將三星Galaxy Watch的生物識別數據整合至藥物開發流程中。
By turning raw physiological data—such as heart rate, sleep patterns, and activity levels—into standardized clinical evidence, this initiative supports more flexible, decentralized clinical trials (DCTs).
透過將原始生理數據（如心率、睡眠模式及活動量）轉化為標準化的臨床證據，這項計畫支持了更靈活、去中心化的臨床試驗（DCTs）。
This approach moves research away from hospital-only settings, reducing the burden on patients while enabling continuous health monitoring in their daily lives.
這種模式讓研究脫離了僅限醫院的環境，減輕病患負擔，同時能在其日常生活中進行持續的健康監測。
Alcedis, a subsidiary of the Huma Group, leverages its decades of expertise in oncology and cardiology to ensure that Samsung’s hardware translates effectively into regulated clinical outcomes.
身為Huma集團旗下的子公司，Alcedis發揮其在腫瘤學與心臟病學領域深耕數十年的專業，確保三星的硬體能有效地轉化為合乎法規的臨床成果。
This partnership bridges the gap between consumer wearables and professional medical research, aiming to shorten development timelines and improve data reliability.
此夥伴關係填補了消費型穿戴裝置與專業醫學研究之間的鴻溝，旨在縮短開發時程並提升數據可靠性。
Ultimately, this synergy seeks to accelerate the delivery of new, life-changing therapies to patients worldwide, marking a pivotal step forward in the evolution of digital-first medical research.
最終，這種協同效應旨在加速將改變生命的新療法提供給全球病患，這標誌著數位優先醫學研究發展邁出了關鍵性的一步。
